vs
拜玛林制药（BMRN）与LOUISIANA-PACIFIC CORP（LPX）财务数据对比。点击上方公司名可切换其他公司
拜玛林制药的季度营收约是LOUISIANA-PACIFIC CORP的1.5倍（$874.6M vs $566.0M），LOUISIANA-PACIFIC CORP净利率更高（-1.4% vs -5.3%，领先3.9%），拜玛林制药同比增速更快（17.0% vs -16.9%），拜玛林制药自由现金流更多（$58.9M vs $-8.0M），过去两年拜玛林制药的营收复合增速更高（16.1% vs -11.6%）
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
路易斯安那-太平洋公司（简称LP）是美国知名建材制造商，成立于1973年，是美国定向结构刨花板（OSB）生产的开创者，总部现位于田纳西州纳什维尔。作为全球最大的OSB生产商，公司还生产工程木建材产品，通过建材分销商、经销商及家居零售中心向建筑商和业主供货。
BMRN vs LPX — 直观对比
营收规模更大
BMRN
是对方的1.5倍
$566.0M
营收增速更快
BMRN
高出33.9%
-16.9%
净利率更高
LPX
高出3.9%
-5.3%
自由现金流更多
BMRN
多$66.9M
$-8.0M
两年增速更快
BMRN
近两年复合增速
-11.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $874.6M | $566.0M |
| 净利润 | $-46.6M | $-8.0M |
| 毛利率 | 68.5% | 15.0% |
| 营业利润率 | -5.1% | -1.6% |
| 净利率 | -5.3% | -1.4% |
| 营收同比 | 17.0% | -16.9% |
| 净利润同比 | -137.3% | -112.9% |
| 每股收益（稀释后） | $-0.22 | $-0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRNLPX
| Q4 25 | $874.6M | $566.0M | ||
| Q3 25 | $776.1M | $663.0M | ||
| Q2 25 | $825.4M | $755.0M | ||
| Q1 25 | $745.1M | $724.0M | ||
| Q4 24 | $747.3M | $681.0M | ||
| Q3 24 | $745.7M | $722.0M | ||
| Q2 24 | $712.0M | $814.0M | ||
| Q1 24 | $648.8M | $724.0M |
净利润BMRNLPX
| Q4 25 | $-46.6M | $-8.0M | ||
| Q3 25 | $-30.7M | $9.0M | ||
| Q2 25 | $240.5M | $54.0M | ||
| Q1 25 | $185.7M | $91.0M | ||
| Q4 24 | $124.9M | $62.0M | ||
| Q3 24 | $106.1M | $90.0M | ||
| Q2 24 | $107.2M | $160.0M | ||
| Q1 24 | $88.7M | $108.0M |
毛利率BMRNLPX
| Q4 25 | 68.5% | 15.0% | ||
| Q3 25 | 82.0% | 19.5% | ||
| Q2 25 | 81.8% | 23.6% | ||
| Q1 25 | 79.7% | 27.2% | ||
| Q4 24 | 81.8% | 23.8% | ||
| Q3 24 | 74.7% | 26.7% | ||
| Q2 24 | 81.7% | 32.3% | ||
| Q1 24 | 80.7% | 29.6% |
营业利润率BMRNLPX
| Q4 25 | -5.1% | -1.6% | ||
| Q3 25 | -6.0% | 2.7% | ||
| Q2 25 | 33.5% | 10.6% | ||
| Q1 25 | 30.0% | 16.6% | ||
| Q4 24 | 21.6% | 11.0% | ||
| Q3 24 | 15.3% | 16.1% | ||
| Q2 24 | 16.9% | 23.8% | ||
| Q1 24 | 13.6% | 20.0% |
净利率BMRNLPX
| Q4 25 | -5.3% | -1.4% | ||
| Q3 25 | -4.0% | 1.4% | ||
| Q2 25 | 29.1% | 7.2% | ||
| Q1 25 | 24.9% | 12.6% | ||
| Q4 24 | 16.7% | 9.1% | ||
| Q3 24 | 14.2% | 12.5% | ||
| Q2 24 | 15.1% | 19.7% | ||
| Q1 24 | 13.7% | 14.9% |
每股收益（稀释后）BMRNLPX
| Q4 25 | $-0.22 | $-0.12 | ||
| Q3 25 | $-0.16 | $0.13 | ||
| Q2 25 | $1.23 | $0.77 | ||
| Q1 25 | $0.95 | $1.30 | ||
| Q4 24 | $0.65 | $0.90 | ||
| Q3 24 | $0.55 | $1.28 | ||
| Q2 24 | $0.55 | $2.23 | ||
| Q1 24 | $0.46 | $1.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $292.0M |
| 总债务越低越好 | — | $348.0M |
| 股东权益账面价值 | $6.1B | $1.7B |
| 总资产 | $7.6B | $2.6B |
| 负债/权益比越低杠杆越低 | — | 0.20× |
8季度趋势，按日历期对齐
现金及短期投资BMRNLPX
| Q4 25 | $1.3B | $292.0M | ||
| Q3 25 | $1.3B | $316.0M | ||
| Q2 25 | $1.2B | $333.0M | ||
| Q1 25 | $1.0B | $256.0M | ||
| Q4 24 | $942.8M | $340.0M | ||
| Q3 24 | $675.4M | $346.0M | ||
| Q2 24 | $972.1M | $317.0M | ||
| Q1 24 | $747.0M | $244.0M |
总债务BMRNLPX
| Q4 25 | — | $348.0M | ||
| Q3 25 | — | $348.0M | ||
| Q2 25 | — | $348.0M | ||
| Q1 25 | — | $348.0M | ||
| Q4 24 | — | $348.0M | ||
| Q3 24 | — | $347.0M | ||
| Q2 24 | — | $347.0M | ||
| Q1 24 | — | $347.0M |
股东权益BMRNLPX
| Q4 25 | $6.1B | $1.7B | ||
| Q3 25 | $6.1B | $1.7B | ||
| Q2 25 | $6.0B | $1.7B | ||
| Q1 25 | $5.8B | $1.7B | ||
| Q4 24 | $5.7B | $1.7B | ||
| Q3 24 | $5.4B | $1.7B | ||
| Q2 24 | $5.3B | $1.7B | ||
| Q1 24 | $5.1B | $1.6B |
总资产BMRNLPX
| Q4 25 | $7.6B | $2.6B | ||
| Q3 25 | $7.6B | $2.6B | ||
| Q2 25 | $7.5B | $2.7B | ||
| Q1 25 | $7.1B | $2.6B | ||
| Q4 24 | $7.0B | $2.6B | ||
| Q3 24 | $6.9B | $2.6B | ||
| Q2 24 | $7.1B | $2.5B | ||
| Q1 24 | $6.9B | $2.5B |
负债/权益比BMRNLPX
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.20× | ||
| Q2 25 | — | 0.20× | ||
| Q1 25 | — | 0.21× | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.6M | $67.0M |
| 自由现金流经营现金流 - 资本支出 | $58.9M | $-8.0M |
| 自由现金流率自由现金流/营收 | 6.7% | -1.4% |
| 资本支出强度资本支出/营收 | 4.7% | 13.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $725.0M | $91.0M |
8季度趋势，按日历期对齐
经营现金流BMRNLPX
| Q4 25 | $99.6M | $67.0M | ||
| Q3 25 | $368.7M | $89.0M | ||
| Q2 25 | $185.3M | $162.0M | ||
| Q1 25 | $174.4M | $64.0M | ||
| Q4 24 | $185.6M | $105.0M | ||
| Q3 24 | $221.5M | $183.0M | ||
| Q2 24 | $118.8M | $212.0M | ||
| Q1 24 | $47.0M | $105.0M |
自由现金流BMRNLPX
| Q4 25 | $58.9M | $-8.0M | ||
| Q3 25 | $340.2M | $5.0M | ||
| Q2 25 | $168.2M | $94.0M | ||
| Q1 25 | $157.6M | $0 | ||
| Q4 24 | $166.1M | $43.0M | ||
| Q3 24 | $203.0M | $139.0M | ||
| Q2 24 | $97.4M | $176.0M | ||
| Q1 24 | $20.9M | $64.0M |
自由现金流率BMRNLPX
| Q4 25 | 6.7% | -1.4% | ||
| Q3 25 | 43.8% | 0.8% | ||
| Q2 25 | 20.4% | 12.5% | ||
| Q1 25 | 21.2% | 0.0% | ||
| Q4 24 | 22.2% | 6.3% | ||
| Q3 24 | 27.2% | 19.3% | ||
| Q2 24 | 13.7% | 21.6% | ||
| Q1 24 | 3.2% | 8.8% |
资本支出强度BMRNLPX
| Q4 25 | 4.7% | 13.3% | ||
| Q3 25 | 3.7% | 12.7% | ||
| Q2 25 | 2.1% | 9.0% | ||
| Q1 25 | 2.3% | 8.8% | ||
| Q4 24 | 2.6% | 9.1% | ||
| Q3 24 | 2.5% | 6.1% | ||
| Q2 24 | 3.0% | 4.4% | ||
| Q1 24 | 4.0% | 5.7% |
现金转化率BMRNLPX
| Q4 25 | — | — | ||
| Q3 25 | — | 9.89× | ||
| Q2 25 | 0.77× | 3.00× | ||
| Q1 25 | 0.94× | 0.70× | ||
| Q4 24 | 1.49× | 1.69× | ||
| Q3 24 | 2.09× | 2.03× | ||
| Q2 24 | 1.11× | 1.32× | ||
| Q1 24 | 0.53× | 0.97× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
LPX
| OS Bvalueadd | $472.0M | 83% |
| Other | $84.0M | 15% |
| Otherproducts | $10.0M | 2% |
